Another phase III Chinese trial is exploring the same outcomes for trans-arterial/intratumoral infusion of anti-PD-1/PD-L1 antibodies and/or the anti-CTLA-4 antibody ipilimumab for several tumor types and includes an advanced HCC cohort (NCT03755739). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.